What clinical trials have been conducted on the medication therapies for hidradenitis suppurativa (HS) treatment?

Updated: Nov 20, 2020
  • Author: Marina Jovanovic, MD, PhD; Chief Editor: William D James, MD  more...
  • Print

A relevant benefit-to-risk ratio analysis can be performed only for the phase 2 trial of adalimumab, since that is the only randomized controlled trial with an appropriate safety analysis that provides the basis to recommend adalimumab as the first-line treatment option in patients with moderate-to-severe hidradenitis suppurativa who were unresponsive to or intolerant of oral antibiotics. [54, 102]

There is very limited or absent randomized controlled trial data in hidradenitis suppurativa for antibiotic therapy, retinoids, oral immunomodulators, and, in particular, there are no randomized controlled trial data investigating the timing of surgery or type of surgical procedure. Interventions currently under investigation include topical antiseptics, the Nd:YAG and carbon dioxide lasers, anakinra (a newer biological treatment that inhibits IL-1, and the PIONEER I and II studies of adalimumab therapy. [102]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!